CARDIFF ONCOLOGY ANNOUNCES EXPANDED ACCESS PROGRAM FOR ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER AS FOLLOW-ON TO FAST TRACK DESIGNATION
NMS Group
June 9, 2020

San Diego, 09.06.2020

For the full press release: https://cardiffoncology.investorroom.com/2020-06-09-Cardiff-Oncology-Announces-Expanded-Access-Program-for-Onvansertib-in-KRAS-Mutated-Metastatic-Colorectal-Cancer-as-Follow-On-to-Fast-Track-Designation

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO